Menu Search
Equities

PTC Therapeutics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
BH3:FRA

PTC Therapeutics Inc

Actions
  • Price (EUR)41.20
  • Today's Change0.20 / 0.49%
  • Shares traded150.00
  • 1 Year change+32.90%
  • Beta0.5386
Data delayed at least 15 minutes, as of Jul 18 2025 07:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year PTC Therapeutics Inc had revenues fall -13.97% from 937.82m to 806.78m, though the company grew net income from a loss of 626.60m to a smaller loss of 363.30m.
Gross margin96.87%
Net profit margin33.55%
Operating margin45.86%
Return on assets26.76%
Return on equity--
Return on investment36.33%
More ▼

Cash flow in USDView more

In 2024, PTC Therapeutics Inc increased its cash reserves by 30.32%, or 185.03m. Cash Flow from Financing totalled 255.87m or 31.71% of revenues. In addition the company used 107.69m for operations while cash from investing totalled 44.18m.
Cash flow per share7.85
Price/Cash flow per share6.18
Book value per share-2.34
Tangible book value per share-4.88
More ▼

Balance sheet in USDView more

PTC Therapeutics Inc appears to have a weak balance sheet, highlighted by its negative owner's equity. Additionally, this company's debt load outweighs its assets while day-to-day operations are losing money. One plus is that there are enough liquid assets to satisfy current obligations, however, this situation is unsustainable over the long run. PTC Therapeutics Inc has considerable financial risk.
Current ratio3.89
Quick ratio3.85
Total debt/total equity--
Total debt/total capital1.08
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.